I. Funke
Research Subjects
I. Funke has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
B Mayer
3 shared publicationsG Riethmüller
3 shared publicationsG Schlimok
3 shared publications- K. W. Jauch
Klinikum Grosshadern, University of Munich, Munich, Germany; Trion Research, Munich, Germany; Klinikum r. d. Isar, Technical University Munich, Munich, Germany
3 shared publications F W Schildberg
2 shared publicationsF. W. Schildberg
Chirurgische Klinik und Poliklinik
2 shared publications
Latest Publications
- 29 August 2006
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 3 (03) , FV43
Individualisierte molekulare Therapie der Pleurakarzinose beim Mammakarzinom
Zielsetzung: Ziel der vorliegenden Studie ist die Entwicklung eines molekularen Therapieansatzes zur Behandlung der Pleurakarzinose beim Mammakarzinom. Die Verbesserung der derzeit ungünstigen Prognose steht hierbei im Vordergrund. Material und Methoden: Bislang wurden 18 maligne Pleuraergüsse immunzytologisch (ABC-Färbung auf Zytospinpräparaten, FACS-Analyse) charakterisiert. Bei der Zelltypisierung wurde der Anteil der Karzinomzellen und verschiendener Immunzellen prozentual bestimmt. Bei der Erstellung des Antigenprofils wurden verschiedene therapierelevante Markermoleküle auf den Tumorzellen nachgewiesen. Basierend auf dieser Ergusscharakterisierung wurden die wahrscheinlich wirksamsten molekularen Therapeutika ausgewählt und ex-vivo funktionell auf ihre Zytotoxizität überprüft (ToxiLight-, TUNEL-Assay). Ergebnisse: Die untersuchten Pleuraergüsse zeigten bezüglich ihrer zellulären Zusammensetzung eine ausgeprägte patientenabhängige Heterogenität, die sowohl für die Karzinomzellen (KL-1, mean 30%, Streubreite 1–80%) als auch für die Immunzellen (CD45, mean 62,8%, Streubreite 5–95% und CD3, mean 49,9%, Streubreite 5–95%) galt. Die molekulare Charakterisierung der Pleurakarzinomzellen ergab, dass die meisten Pleuraergüsse MUC-1 (83%), EGF-R (78%) und EpCAM (72%) positiv waren, gefolgt von UPA-R (67%) und CEA (56%). Seltener waren HER2/neu (33,3%) und ER (22%) bzw. PgR (0,1%) nachweisbar. Der Anteil der Antigen-positiven Tumorzellen zeigte ein ähnliches Verteilungsmuster. Die meisten Karzinomzellen exprimierten UPA-R (82%), EpCAM (75%), sowie MUC-1 und EGF-R (jeweils 72%). Weniger häufig dagegen waren ER- (59%), HER2/neu (48%) und PgR (10%)- positive Tumorzellen detektierbar. Die ex-vivo Untersuchungen belegten eine gute Übereinstimmung zwischen der deskriptiven und funktionellen Ergussanalyse (pZusammenfassung: Die zelluläre und molekulare Charakterisierung der Pleurakarzinose bildet eine selektive Entscheidungsgrundlage für die individualisierte Therapie des metastasierten Mammakarzinoms.
- 29 August 2006
- Published by Georg Thieme Verlag KG in Senologie - Zeitschrift für Mammadiagnostik und -therapie
- Vol. 3 (03) , FV43
Individualisierte molekulare Therapie der Pleurakarzinose beim Mammakarzinom
Zielsetzung: Ziel der vorliegenden Studie ist die Entwicklung eines molekularen Therapieansatzes zur Behandlung der Pleurakarzinose beim Mammakarzinom. Die Verbesserung der derzeit ungünstigen Prognose steht hierbei im Vordergrund. Material und Methoden: Bislang wurden 18 maligne Pleuraergüsse immunzytologisch (ABC-Färbung auf Zytospinpräparaten, FACS-Analyse) charakterisiert. Bei der Zelltypisierung wurde der Anteil der Karzinomzellen und verschiendener Immunzellen prozentual bestimmt. Bei der Erstellung des Antigenprofils wurden verschiedene therapierelevante Markermoleküle auf den Tumorzellen nachgewiesen. Basierend auf dieser Ergusscharakterisierung wurden die wahrscheinlich wirksamsten molekularen Therapeutika ausgewählt und ex-vivo funktionell auf ihre Zytotoxizität überprüft (ToxiLight-, TUNEL-Assay). Ergebnisse: Die untersuchten Pleuraergüsse zeigten bezüglich ihrer zellulären Zusammensetzung eine ausgeprägte patientenabhängige Heterogenität, die sowohl für die Karzinomzellen (KL-1, mean 30%, Streubreite 1–80%) als auch für die Immunzellen (CD45, mean 62,8%, Streubreite 5–95% und CD3, mean 49,9%, Streubreite 5–95%) galt. Die molekulare Charakterisierung der Pleurakarzinomzellen ergab, dass die meisten Pleuraergüsse MUC-1 (83%), EGF-R (78%) und EpCAM (72%) positiv waren, gefolgt von UPA-R (67%) und CEA (56%). Seltener waren HER2/neu (33,3%) und ER (22%) bzw. PgR (0,1%) nachweisbar. Der Anteil der Antigen-positiven Tumorzellen zeigte ein ähnliches Verteilungsmuster. Die meisten Karzinomzellen exprimierten UPA-R (82%), EpCAM (75%), sowie MUC-1 und EGF-R (jeweils 72%). Weniger häufig dagegen waren ER- (59%), HER2/neu (48%) und PgR (10%)- positive Tumorzellen detektierbar. Die ex-vivo Untersuchungen belegten eine gute Übereinstimmung zwischen der deskriptiven und funktionellen Ergussanalyse (pZusammenfassung: Die zelluläre und molekulare Charakterisierung der Pleurakarzinose bildet eine selektive Entscheidungsgrundlage für die individualisierte Therapie des metastasierten Mammakarzinoms.
- 10 October 2002
- Vol. 144 (41) , 37-9
[Detection of disseminated tumor cells in bone marrow--currently of no practical therapeutic value].
Development of metastases in cancer patients is usually due to tumour cells seeding from the primary. These disseminated cells can be detected in blood or bone marrow with the aid of immunocytochemical methods. The clinical significance of this is, however, still controversial. With the aim of determining the prognostic value of disseminated tumour cells, a meta-analysis of 20 publications reporting results based on data collected from a total of 2494 breast cancer patients, was carried out. The outcome of the meta-analysis was that 14 of the 20 studies provided evidence suggesting positive bone marrow findings to be an unfavorable prognostic factor. Five out of twelve studies provided multivariate analytic evidence of an impact of bone marrow status on recurrence-free survival. In five out of twelve studies, a univariate analysis showed a positive bone marrow finding to correlate significantly with overall survival, while a multivariate analysis found such a correlation in only two out of six studies. Owing to a lack of standardization, the results of the individual studies are not directly comparable. Against this background it is too early to say whether the detection of disseminated tumour cells in the bone marrow can be used as a prognostic factor with an impact on therapeutic strategies.
- 10 October 2002
- Vol. 144 (41) , 37-9
[Detection of disseminated tumor cells in bone marrow--currently of no practical therapeutic value].
Development of metastases in cancer patients is usually due to tumour cells seeding from the primary. These disseminated cells can be detected in blood or bone marrow with the aid of immunocytochemical methods. The clinical significance of this is, however, still controversial. With the aim of determining the prognostic value of disseminated tumour cells, a meta-analysis of 20 publications reporting results based on data collected from a total of 2494 breast cancer patients, was carried out. The outcome of the meta-analysis was that 14 of the 20 studies provided evidence suggesting positive bone marrow findings to be an unfavorable prognostic factor. Five out of twelve studies provided multivariate analytic evidence of an impact of bone marrow status on recurrence-free survival. In five out of twelve studies, a univariate analysis showed a positive bone marrow finding to correlate significantly with overall survival, while a multivariate analysis found such a correlation in only two out of six studies. Owing to a lack of standardization, the results of the individual studies are not directly comparable. Against this background it is too early to say whether the detection of disseminated tumour cells in the bone marrow can be used as a prognostic factor with an impact on therapeutic strategies.
- 1 February 1998
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 16 (2) , 557-566
Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated.
PURPOSE: In 1997, the immunocytologic detection of isolated tumor cells in bone marrow, termed micrometastasis, will be optionally included in the tumor-node-metastasis (TNM) classification indicated M1(i). In the present meta-analyses, 20 studies, which included 2,494 patients, regarding the prognostic influence of a positive bone marrow micrometastases (BMM) status on relapse-free and/or overall survival were analyzed. MATERIALS AND METHODS: The literature search included the Medline and Current Contents bibliographic data bases from August 1980 to June 1997. The statistical evaluation considered the prognostic influence of the prevalence of micrometastatic cells in bone marrow on relapse-free and/or overall survival. The comparable effect estimate and its corresponding 95% confidence interval (CI) were calculated with the Mantel-Haenszel method using the originally published data of the retrieved studies. RESULTS: The presence of epithelial cells in bone marrow was detectable in all carcinoma types, with a median prevalence of approximately 35%. Fourteen of 20 studies found a positive correlation between positive BMM status and reduced relapse-free survival by univariate analysis, but only five of 11 studies confirmed positive BMM status as an independent predictor of short disease-free survival. Regarding overall survival, positive BMM status was identified univariately in five of 12 studies, but multivariately in only two studies, as an independent factor of poor survival. Despite the heterogeneity of the studies, calculation of the relative risk (RR) for reduced relapse-free survival was possible for breast cancer, which resulted in a Mantel-Haenszel RR (RR(MH)) of 1.34 (95% CI, 1.27 to 1.42). CONCLUSION: In conclusion, the results suggest that the prognostic impact of epithelial cells in bone marrow remains to be substantiated by further studies using standardized methodic protocols before its entrance in the TNM classification.
- 1 February 1998
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 16 (2) , 557-566
Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated.
PURPOSE: In 1997, the immunocytologic detection of isolated tumor cells in bone marrow, termed micrometastasis, will be optionally included in the tumor-node-metastasis (TNM) classification indicated M1(i). In the present meta-analyses, 20 studies, which included 2,494 patients, regarding the prognostic influence of a positive bone marrow micrometastases (BMM) status on relapse-free and/or overall survival were analyzed. MATERIALS AND METHODS: The literature search included the Medline and Current Contents bibliographic data bases from August 1980 to June 1997. The statistical evaluation considered the prognostic influence of the prevalence of micrometastatic cells in bone marrow on relapse-free and/or overall survival. The comparable effect estimate and its corresponding 95% confidence interval (CI) were calculated with the Mantel-Haenszel method using the originally published data of the retrieved studies. RESULTS: The presence of epithelial cells in bone marrow was detectable in all carcinoma types, with a median prevalence of approximately 35%. Fourteen of 20 studies found a positive correlation between positive BMM status and reduced relapse-free survival by univariate analysis, but only five of 11 studies confirmed positive BMM status as an independent predictor of short disease-free survival. Regarding overall survival, positive BMM status was identified univariately in five of 12 studies, but multivariately in only two studies, as an independent factor of poor survival. Despite the heterogeneity of the studies, calculation of the relative risk (RR) for reduced relapse-free survival was possible for breast cancer, which resulted in a Mantel-Haenszel RR (RR(MH)) of 1.34 (95% CI, 1.27 to 1.42). CONCLUSION: In conclusion, the results suggest that the prognostic impact of epithelial cells in bone marrow remains to be substantiated by further studies using standardized methodic protocols before its entrance in the TNM classification.
- 1 January 1998
- Vol. 115, 631-4
[Expression of Lewis blood group antigens in stomach carcinoma induces metastatic potential].
In a series of gastric cancer patients twenty-eight percent of the primary tumors expressed high levels of the Lewis carbohydrate. This correlated significantly with clinicopathological parameters of advanced disease (tumor size of > 50 mm, M1 stage, UICC stage IIIB/IV). In multivariate analysis, high Lewis expression was found to be a new independent factor of poor prognosis. In addition, Lewis was expressed on solid metastases and micrometastatic cells originating from Lewis positive primary tumors. The data suggest that Lewis positive tumor cells may have an advantage in penetrating secondary organs because, like leukocytes, they can specifically adhere to activated vascular endothelia.
- 1 January 1998
- Vol. 115, 631-4
[Expression of Lewis blood group antigens in stomach carcinoma induces metastatic potential].
In a series of gastric cancer patients twenty-eight percent of the primary tumors expressed high levels of the Lewis carbohydrate. This correlated significantly with clinicopathological parameters of advanced disease (tumor size of > 50 mm, M1 stage, UICC stage IIIB/IV). In multivariate analysis, high Lewis expression was found to be a new independent factor of poor prognosis. In addition, Lewis was expressed on solid metastases and micrometastatic cells originating from Lewis positive primary tumors. The data suggest that Lewis positive tumor cells may have an advantage in penetrating secondary organs because, like leukocytes, they can specifically adhere to activated vascular endothelia.
- 1 April 1993
- Vol. 53 (7) , 1690-5
E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration.
Expression of the epithelial cell adhesion molecule E-cadherin in primary and metastatic gastric carcinoma was examined using immunohistochemical analyses. Compared to normal mucosa, 92% of the primary tumors (n = 60) showed reduced E-cadherin expression, suggesting that down-regulation of this cell adhesion molecule is a common early event in gastric tumorigenesis. No significant correlation was found between E-cadherin expression and tumor diameter, lymphatic vessel invasion, Borrmann classification, lymph node status, or manifest metastases. Although advanced tumors (tumor stage 3/4) showed a loss of E-cadherin-positive cells (< or = 50% cells/lesion, P = 0.0168), the most significant correlation was observed between low E-cadherin expression and cellular dedifferentiation (grading 3/4, P = 0.0001) and disintegration of tissue architecture (Lauren and WHO classifications, P = 0.0001). Low E-cadherin expression (< or = 50% cells/lesion) was associated with tumor recurrence (P = 0.0013) and mortality (P = 0.0246). E-cadherin expression in metastatic lesions (n = 58) also correlated with the degree of glandular differentiation (P = 0.0001). Significant correlation (rs = 0.686) was observed between E-cadherin expression in primary and metastatic lesions from individual patients (n = 39). However, while metastases derived from E-cadherin-negative tumors remained negative, those originating from E-cadherin-positive tumors frequently demonstrated increased levels of expression. Evaluation of multiple metastases in 11 patients revealed uniformly strong E-cadherin expression in liver metastases, suggesting a possible regulatory role of the microenvironment.
- 1 April 1993
- Vol. 53 (7) , 1690-5
E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration.
Expression of the epithelial cell adhesion molecule E-cadherin in primary and metastatic gastric carcinoma was examined using immunohistochemical analyses. Compared to normal mucosa, 92% of the primary tumors (n = 60) showed reduced E-cadherin expression, suggesting that down-regulation of this cell adhesion molecule is a common early event in gastric tumorigenesis. No significant correlation was found between E-cadherin expression and tumor diameter, lymphatic vessel invasion, Borrmann classification, lymph node status, or manifest metastases. Although advanced tumors (tumor stage 3/4) showed a loss of E-cadherin-positive cells (< or = 50% cells/lesion, P = 0.0168), the most significant correlation was observed between low E-cadherin expression and cellular dedifferentiation (grading 3/4, P = 0.0001) and disintegration of tissue architecture (Lauren and WHO classifications, P = 0.0001). Low E-cadherin expression (< or = 50% cells/lesion) was associated with tumor recurrence (P = 0.0013) and mortality (P = 0.0246). E-cadherin expression in metastatic lesions (n = 58) also correlated with the degree of glandular differentiation (P = 0.0001). Significant correlation (rs = 0.686) was observed between E-cadherin expression in primary and metastatic lesions from individual patients (n = 39). However, while metastases derived from E-cadherin-negative tumors remained negative, those originating from E-cadherin-positive tumors frequently demonstrated increased levels of expression. Evaluation of multiple metastases in 11 patients revealed uniformly strong E-cadherin expression in liver metastases, suggesting a possible regulatory role of the microenvironment.
- 1 November 1991
- Vol. 62 (11) , 805-9
[Detection of tumor cells in bone marrow: a deciding aid for adjuvant therapy in node negative patients with breast cancer. Concept for a multicenter study and results of the pilot phase].
In node-negative breast cancer some 30% of patients will suffer a tumor relapse, despite primary curative therapeutic intervention. An adjuvant therapy is therefore in discussion, especially in presence of risk factors. Immunocytochemical staining of cytokeratin-positive cells in bone marrow aspirates with monoclonal antibodies offers a chance to detect tumorcell dissemination at an early stage of single tumor cells. In 103 consecutive patients 50% showed a positive bone marrow aspirate, in node negative patients still 34%. Based on the literature and tumor biology this method may be valid in selecting node-negative breast cancer patients for adjuvant therapy. In a prospective multi-center trial the prognostic value will be evaluated in regard to other prognostic factors. Additionally the benefit of an adjuvant therapy will be studied in a randomized prospective trial.
- 1 November 1991
- Vol. 62 (11) , 805-9
[Detection of tumor cells in bone marrow: a deciding aid for adjuvant therapy in node negative patients with breast cancer. Concept for a multicenter study and results of the pilot phase].
In node-negative breast cancer some 30% of patients will suffer a tumor relapse, despite primary curative therapeutic intervention. An adjuvant therapy is therefore in discussion, especially in presence of risk factors. Immunocytochemical staining of cytokeratin-positive cells in bone marrow aspirates with monoclonal antibodies offers a chance to detect tumorcell dissemination at an early stage of single tumor cells. In 103 consecutive patients 50% showed a positive bone marrow aspirate, in node negative patients still 34%. Based on the literature and tumor biology this method may be valid in selecting node-negative breast cancer patients for adjuvant therapy. In a prospective multi-center trial the prognostic value will be evaluated in regard to other prognostic factors. Additionally the benefit of an adjuvant therapy will be studied in a randomized prospective trial.
- 1 September 1991
- Vol. 51 (17) , 4712-5
Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells.
An astoundingly high frequency of micrometastatic cells have been found in bone marrow aspirates of patients with colon carcinomas (G. Schlimok et al., J. Clin. Oncol., 8:831-837, 1990), although these tumors very rarely metastasize to the skeleton. This observation has raised questions about the malignant potential of such cells. In a first attempt to characterize this potential, we have assessed the expression of major histocompatibility complex (MHC) class I antigens on bone marrow micrometastases, inasmuch as down-regulation of these molecules is a potential mechanism to escape from MHC class I-restricted lysis by cytotoxic T-cells. The two groups of cancer patients compared were those with tumors known to rarely (stomach and colon cancer) or frequently (breast cancer) manifest skeleton metastases. Bone marrow aspirates taken from these patients were probed for individual disseminated tumor cells using the immunoalkaline phosphatase technique with monoclonal antibody CK2 to the epithelial differentiation antigen cytokeratin 18 (CK-18), as described previously (G. Schlimok et al., Proc. Natl. Acad. Sci. USA, 84:8672-8676, 1987). Specimens containing CK18-positive cells were colabeled with monoclonal antibody W6/32 directed to a framework (or nonpolymorphic) antigenic determinant of MHC class I heavy chains associated with beta 2-microglobulin. W6/32-positive CK-18-positive cells could be detected in 25 of 54 patients (46.3%) with significantly higher incidences in 26 breast cancer patients (61.9%) as compared to 28 patients with carcinomas of the stomach and colon (27.3 and 29.4%). Independent from the origin of the primary carcinoma, the incidence of W6/32-negative CK18-positive cells was positively correlated to both the differentiation grade of the primary tumor (P less than 0.05) and appeared to be linked to the occurrence of regional lymph node metastases (statistically not significant) determined by conventional histological examination. The present results demonstrate for the first time that down-regulation of MHC expression on individual micrometastatic cells correlates to the differential pattern of metastasis obtained by comparing breast and gastrointestinal carcinomas. This finding together with the suggestive link to clinical risk factors supports the significance of reduced MHC class I expression for the survival of residual metastatic cells which is a major determinant of prognosis for patients with solid tumors.
- 1 September 1991
- Vol. 51 (17) , 4712-5
Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells.
An astoundingly high frequency of micrometastatic cells have been found in bone marrow aspirates of patients with colon carcinomas (G. Schlimok et al., J. Clin. Oncol., 8:831-837, 1990), although these tumors very rarely metastasize to the skeleton. This observation has raised questions about the malignant potential of such cells. In a first attempt to characterize this potential, we have assessed the expression of major histocompatibility complex (MHC) class I antigens on bone marrow micrometastases, inasmuch as down-regulation of these molecules is a potential mechanism to escape from MHC class I-restricted lysis by cytotoxic T-cells. The two groups of cancer patients compared were those with tumors known to rarely (stomach and colon cancer) or frequently (breast cancer) manifest skeleton metastases. Bone marrow aspirates taken from these patients were probed for individual disseminated tumor cells using the immunoalkaline phosphatase technique with monoclonal antibody CK2 to the epithelial differentiation antigen cytokeratin 18 (CK-18), as described previously (G. Schlimok et al., Proc. Natl. Acad. Sci. USA, 84:8672-8676, 1987). Specimens containing CK18-positive cells were colabeled with monoclonal antibody W6/32 directed to a framework (or nonpolymorphic) antigenic determinant of MHC class I heavy chains associated with beta 2-microglobulin. W6/32-positive CK-18-positive cells could be detected in 25 of 54 patients (46.3%) with significantly higher incidences in 26 breast cancer patients (61.9%) as compared to 28 patients with carcinomas of the stomach and colon (27.3 and 29.4%). Independent from the origin of the primary carcinoma, the incidence of W6/32-negative CK18-positive cells was positively correlated to both the differentiation grade of the primary tumor (P less than 0.05) and appeared to be linked to the occurrence of regional lymph node metastases (statistically not significant) determined by conventional histological examination. The present results demonstrate for the first time that down-regulation of MHC expression on individual micrometastatic cells correlates to the differential pattern of metastasis obtained by comparing breast and gastrointestinal carcinomas. This finding together with the suggestive link to clinical risk factors supports the significance of reduced MHC class I expression for the survival of residual metastatic cells which is a major determinant of prognosis for patients with solid tumors.
- 1 March 1988
- Vol. 38, 435-7
[Monoclonal antibodies--new probes for diagnosis and therapy. Their use as an example of the micrometastasizing of solid tumors].
Monoclonal antibody CK2, recognizing component No. 18, appeared to be the most suitable reagent for the detection of epithelial tumor cells in bone marrow. Its specificity was confirmed in a double-marker staining procedure (combination of APAAP-technique and radioautography). CK2 positive cells were demonstrated not to reveal any cross-reactivity with an antibody directed against the "leucocyte common antigen". A significant correlation between the presence of epithelial tumor cells in bone marrow and certain conventional risk factors was found. A more detailed phenotypic characterisation could demonstrate the expression of proliferation associated antigens on these cells. Furthermore in an immunotherapeutic approach with monoclonal antibody 17-1A, labelling of the disseminated tumor cells in bone marrow after infusion of the antibody was shown.
- 1 March 1988
- Vol. 38, 435-7
[Monoclonal antibodies--new probes for diagnosis and therapy. Their use as an example of the micrometastasizing of solid tumors].
Monoclonal antibody CK2, recognizing component No. 18, appeared to be the most suitable reagent for the detection of epithelial tumor cells in bone marrow. Its specificity was confirmed in a double-marker staining procedure (combination of APAAP-technique and radioautography). CK2 positive cells were demonstrated not to reveal any cross-reactivity with an antibody directed against the "leucocyte common antigen". A significant correlation between the presence of epithelial tumor cells in bone marrow and certain conventional risk factors was found. A more detailed phenotypic characterisation could demonstrate the expression of proliferation associated antigens on these cells. Furthermore in an immunotherapeutic approach with monoclonal antibody 17-1A, labelling of the disseminated tumor cells in bone marrow after infusion of the antibody was shown.